The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.
Your search for supplemental oxygen returned 11 results
The studies evaluated routine clinical practice data from more than 800 hospitals in the US.
The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.
The update was based on data from the COV-BARRIER study.
Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.
The EUA was issued based on 4 randomized controlled clinical trials that evaluated the efficacy and safety of Actemra in more than 5500 hospitalized patients with COVID-19.
Shortly after an EUA was issued, Genentech announced that tocilizumab (marketed under the brand name Actemra) was in shortage.
Actemra (tocilizumab) is an interleukin-6 receptor antagonist.
Kineret is an interleukin-1 receptor antagonist.
InflaRx is working to increase supply of the product in the US as quickly as possible.